CATB:NSD-Catabasis Pharmaceuticals, Inc (USD)

COMMON STOCK | Biotechnology | NSD

Last Closing Price

USD 6.24

Change

-0.05 (-0.79)%

Market Cap

USD 0.12B

Volume

0.21M

Average Target Price

USD 15.00 (+140.38%)
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

Catabasis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics in the United States. Its lead product candidate is edasalonexent, an oral small molecule that inhibits nuclear factor kappa-light-chain-enhancer of activated B cells, which is in Phase III clinical trial for the treatment of duchenne muscular dystrophy (DMD). The company is also developing CAT-5571 for the treatment of cystic fibrosis. Catabasis Pharmaceuticals, Inc. has a preclinical research collaboration with the Jain Foundation to study edasalonexent in dysferlinopathy; and an agreement with the Bill & Melinda Gates Medical Research Institute to study CAT-5571 in drug-sensitive and drug-resistant tuberculosis. The company was founded in 2008 and is based in Boston, Massachusetts.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2020-09-28 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
VRTX Vertex Pharmaceuticals Incorpo..

-0.45 (-0.17%)

USD69.85B 33.27 26.59
REGN Regeneron Pharmaceuticals, Inc

-2.14 (-0.37%)

USD61.08B 21.61 16.69
SGEN Seattle Genetics, Inc

+5.56 (+3.01%)

USD32.18B N/A N/A
MRNA Moderna, Inc

+1.08 (+1.55%)

USD27.41B N/A N/A
ALXN Alexion Pharmaceuticals, Inc

-1.13 (-0.99%)

USD25.08B 29.87 27.00
BGNE BeiGene, Ltd

-1.75 (-0.62%)

USD24.87B N/A N/A
RPRX Royalty Pharma plc

+1.14 (+2.85%)

USD24.33B 34.81 9.50
GMAB Genmab A/S

+0.93 (+2.58%)

USD23.71B 25.56 2.87
IMMU Immunomedics, Inc

+0.16 (+0.19%)

USD19.73B N/A N/A
INCY Incyte Corporation

+3.81 (+4.40%)

USD18.93B 47.64 35.20

ETFs Containing CATB

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 5.58% 58% F 68% D+
Dividend Return N/A N/A N/A N/A N/A
Total Return 5.58% 58% F 67% D+
Trailing 12 Months  
Capital Gain 15.56% 48% F 68% D+
Dividend Return N/A N/A N/A N/A N/A
Total Return 15.56% 48% F 68% D+
Trailing 5 Years  
Capital Gain -92.29% 19% F 6% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -92.29% 19% F 6% F
Average Annual (5 Year Horizon)  
Capital Gain -35.82% N/A N/A 3% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -35.82% N/A N/A 3% F
Risk Return Profile  
Volatility (Standard Deviation) 33.09% N/A N/A 42% F
Risk Adjusted Return -108.25% N/A N/A 3% F
Market Capitalization 0.12B 32% F 33% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio 2.60 65% D 43% F
Price / Cash Flow Ratio -4.52 45% F 73% C
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity -64.92% 51% F 20% F
Return on Invested Capital -76.67% 38% F 12% F
Return on Assets -36.72% 31% F 9% F
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Short Ratio 1.79 65% D 65% D
Short Percent 4.79% 61% D- 41% F
Beta 1.73 36% F 20% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:
Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.